Gábor Pál

9PUBLICATIONS
35CO-AUTHORS
Gene and molecular therapyMedical infection agents (incl. prions)Proteins and peptidesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Characterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Dec 18, 2025
Efficient production of fully active, SARS-CoV-2-priming, wildtype TMPRSS2 ectodomain via co-expression of HAI-2 allows for both auto- and cross-activation mechanisms.

Barbara Végh, Andrea Kocsis, József Dobó

|May 15, 2025
Elevated Plasma MBL Levels Are Associated With Risk of Future Venous Thromboembolism: The HUNT Study.

Christabel Esi Damoah, Solveig M Valderhaug, Omri Snir

|Apr 29, 2025
To be, or not to be cleaved: Directed evolution of a canonical serine protease inhibitor against active and inactive protease pair identifies binding loop residue critical for prevention of proteolytic cleavage.

Zsombor Köller, Bálint Zoltán Németh, Bence Kiss

|Apr 14, 2025
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury.

Anjan K Bongoni, Bence Kiss, Jennifer L McRae

|Sep 20, 2024
The High-Affinity Chymotrypsin Inhibitor Eglin C Poorly Inhibits Human Chymotrypsin-Like Protease: Gln192 and Lys218 Are Key Determinants.

Bálint Zoltán Németh, Bence Kiss, Miklós Sahin-Tóth

|Jul 13, 2024
SARS-CoV-2 Nucleocapsid Protein Is Not Responsible for Over-Activation of Complement Lectin Pathway.

Andrea Kocsis, Dalma Bartus, Edit Hirsch

Pageof 2

Frequent Collaborators

4 joint publications

Péter Gál

3 joint publications

Andrea Kocsis

3 joint publications

József Dobó

2 joint publications

Eszter Boros